Advertisement Pharmaceutical Business review - Page 42 of 5263 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 3, 2026

Kairos Pharma signs deal for Celyn Therapeutics’ CL-273

Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics, a company backed by OrbiMed and Torrey Pines Investment.

CL-273 targets resistant mutations from EGFR tyrosine kinase inhibitor treatment. Credit: Innovative Creation / Shutterstock.com.